MedTrace Logo

Rapamycin and Infection-related Illness

NCT07054320 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2026-02-17

No results posted yet for this study

Summary

Conduct a 6-month observational pilot clinical trial to evaluate the safety, monitor the adverse reactions and observe the preliminary effectiveness of medical treatment with oral rapamycin \[Rapamune (Sirolimus)\] in a total of 15 adults, 18 years and older toward preventing and lowering the severity of infectious disease or infection-related illness.

Rapamune (Sirolimus) is not approved by the United States Food and Drug Administration (FDA) to prevent and lessen the severity of infection-related illness or infectious disease. Rapamune (Sirolimus) is approved by the FDA for other indications.

The main procedures in the study include:

* Blood tests to examine cholesterol, lipids, blood platelet counts, inflammation and infection-related health parameters
* Questionnaires to examine brain function, mental health, symptoms, overall health status and quality of life
* Electrocardiogram (ECG to measure heart function)
* Resting diastolic and systolic blood pressure

Conditions

Interventions

OTHER

Observational procedures

Patients at the Hoskinson Health and Wellness Clinic qualifying for treatment with Rapamune (Sirolimus) receive a prescription from their physician during clinic visits as part of their standard health care. This study will evaluate the safety, monitor the adverse reactions and observe the preliminary effectiveness of physician-prescribed medical treatment with oral rapamycin \[Rapamune (Sirolimus)\] in a total of 15 adults, 18 years and older toward preventing and lowering the severity of infectious disease or infection-related illness.

Sponsors & Collaborators

  • Hoskinson Health and Wellness Clinic

    lead INDUSTRY

Principal Investigators

  • William Hoskinson, DO · Hoskinson Health and Wellness Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-08-06
Primary Completion
2026-04-30
Completion
2026-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07054320 on ClinicalTrials.gov